New shot for fatty liver disease enters human testing

NCT ID NCT07427680

Recruiting now Disease control Sponsor: Tangram Therapeutics Plc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an investigational drug called TGM-312-SC01, given as a shot, for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. It first checks safety and drug levels in healthy adults, then in people with MASH. The trial is currently recruiting 99 participants aged 18 to 70.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TGM-312-SC01 (an investigational drug given as a shot under the skin)
What this could lead to: If successful, this could point toward a new treatment option for MASH, a serious liver disease with no approved therapies.
What could go wrong: This is an early-phase trial with only 99 participants, so results may not confirm effectiveness. The drug may cause side effects or fail to improve liver health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Contacts and locations

Show contact details

Locations

Richmond Pharmacology
RECRUITING

London, United Kingdom

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.